会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
    • 5-HT6受体的配体,药物组合物,其生产和使用方法
    • US20110046368A1
    • 2011-02-24
    • US12741006
    • 2007-11-15
    • Andrey Alexandrovich IvashchenkoAlexander Vasilievich IvashchenkoSergey Yevgenievich TkachenkoIlya Matusovich OkunNikolay Filippovich Savchuk
    • Andrey Alexandrovich IvashchenkoAlexander Vasilievich IvashchenkoSergey Yevgenievich TkachenkoIlya Matusovich OkunNikolay Filippovich Savchuk
    • C07D487/04C07D471/04C07D473/04
    • C07D487/04C07D471/04C07D519/00
    • The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role.Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT6 ligands. Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line represents a single or a double bond; n=1, 2 or 3.
    • 本发明涉及含有5-HT 6受体作为活性成分的所述新型配体的药物组合物和用于人和用于治疗中枢神经系统疾病和病症的温血动物的新型药物的5-HT 6受体的新配体, 在5-HT6受体诱导的神经调节因子的发病机理中起着重要的作用。 通式1的氮杂环化合物或其外消旋体或光学或几何异构体或其药学上可接受的盐和/或水合物用作5-HT 6配体。 其中R2和R3彼此独立地表示选自氢的氨基取代基; 取代羰基; 取代的氨基羰基; 取代的氨基硫代羰基; 取代磺酰基; 任选被C 6 -C 10芳基氨基羰基,杂环基,C 6 -C 10 - 芳基氨基羰基,C 6 -C 10 - 芳基氨基硫代羰基,C 5 -C 10 - 氮杂杂芳基,任选取代的羧基,硝基,任选取代的芳基取代的C 1 -C 5 - 任选取代的C 1 -C 5 - 烷基,C 1 -C 5 - 烷氧基,C 1 -C 5 - 烯基,C 1 -C 5 - 炔基,卤素,三氟甲基, CN-基团,羧基,任选取代的芳基,任选取代的杂环基,取代的磺酰基,任选取代的羧基; 伴随虚线的实线表示单键或双键; n = 1,2或3。
    • 10. 发明申请
    • STIMULATORS OF INCRETIN HORMONES SECRETION, METHOD FOR PREPARATION AND USE THEREOF
    • 刺激素分泌物,其制备和使用方法
    • US20140100216A1
    • 2014-04-10
    • US14118895
    • 2012-05-12
    • Nikolay Filippovich SavchukSergey Yevgenievich TkachenkoDenis Yevgenievich Nazarenkov
    • Nikolay Filippovich SavchukSergey Yevgenievich TkachenkoDenis Yevgenievich Nazarenkov
    • C07D267/14C07D413/14C07D498/04C07D413/12A61K31/553A61K45/06
    • C07D267/14A61K31/553A61K45/06C07D413/06C07D413/10C07D413/12C07D413/14C07D498/04
    • The invention relates to the area of medicinal chemistry, pharmacology and medicine and includes description of pharmaceutical compositions and combined medicaments on the base of secretion stimulators and protectors of incretin hormones for treatment of metabolic diseases (among them, diabetes, obesity, metabolic syndrome and the like). The invention consists in that that pharmaceutical composition or combined medicament comprises a derivative of tetrahydrobenzo[f][1,4]oxazepine—either nonsteroidal agonist of bile aids receptor TGR5, or one of endogenous bile acids which stimulate incretin hormones secretion, and also one of the known inhibitors of DPP-IV proteinase. In this case administration of TGR5 agonists is carried out peroral, and administration of endogenous bile acids is exercised rectal in the form of suppository or gel. As proteinase DPP-IV inhibitors could be used Vildagliptin, Saxagliptin, Sitagliptin, Teneligliptin, Linagliptin, Dutogliptin, Alogliptin, Gemigliptin, Carmegliptin and the like. Besides, the invention includes description of novel tetrahydrobenzo[f][1,4]oxazepine derivatives—nonsteroidal agonist of bile aids receptors TGR5, and also methods for their preparation. The invention provides enhancement of therapy effectiveness owing to synergetic action of the components, thus making possible simultaneous treatment of diabetes, and obesity, other metabolic diseases and their cardiovascular and renal complications.
    • 本发明涉及药物化学,药理学和药物领域,包括在分泌刺激剂的基础上的药物组合物和组合药物的描述,以及用于治疗代谢疾病的肠激素激素的保护剂(其中,糖尿病,肥胖症,代谢综合征和 喜欢)。 本发明包括:药物组合物或组合药物包含四氢苯并[f] [1,4]氧氮杂-胆汁辅助受体TGR5的非甾体激动剂或刺激肠降血糖素激素分泌的内源性胆汁酸之一的衍生物,以及一种 已知的DPP-IV蛋白酶抑制剂。 在这种情况下,通过口服施用TGR5激动剂,并以栓剂或凝胶的形式施用内源性胆汁酸。 由于蛋白酶DPP-IV抑制剂可以使用维格列汀,沙格列汀,西他列汀,替奈米汀,利那格列汀,杜曲列汀,阿格列汀,吉格列汀,卡米利宁等。 此外,本发明还包括描述新型四氢苯并[f] [1,4]恶唑嘌呤衍生物 - 胆汁辅助受体TGR5的非甾体激动剂及其制备方法。 本发明由于组分的协同作用提高了治疗效果,从而使糖尿病和肥胖,其他代谢疾病及其心血管和肾脏并发症成为可能的同时治疗。